Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 7/20 | 1.00 |
| ▸ | GPR183 | P32249 | 1/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.35 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.35 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29954047 | 1.00 | CYP2A6 (1.00) | CYP2A6GPR183PRKCIL3MBTL1ALDH1A1 | |
| SCHEMBL1125942 | 0.85 | CYP2A6 (1.00) | CYP2A6PRKCIPIK3CB | |
| SCHEMBL29569100 | 0.85 | CYP2A6 (1.00) | CYP2A6PRKCIPIK3CB | |
| SCHEMBL18029032 | 0.81 | CYP2A6 (0.68) | CYP2A6GPR183PRKCIL3MBTL1ALDH1A1 | |
| SCHEMBL28018792 | 0.77 | CYP2A6 (0.62) | CYP2A6ALDH1A1TSHRKDM4EPTGS2 | |
| SCHEMBL757446 | 0.77 | CYP2A6 (0.62) | CYP2A6ALDH1A1TSHRKDM4EPTGS2 | |
| SCHEMBL29952158 | 0.77 | CYP2A6 (0.62) | CYP2A6ALDH1A1 | |
| SCHEMBL1126156 | 0.77 | CYP2A6 (0.62) | CYP2A6ALDH1A1 | |
| SCHEMBL2945804 | 0.76 | CYP2A6 (0.61) | CYP2A6GPR183ALDH1A1TSHRMAPT | |
| SCHEMBL2945800 | 0.76 | CYP2A6 (0.61) | CYP2A6GPR183ALDH1A1TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145601-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | SATYA THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| WO-2024219864-A1 | NOVEL COMPOUND EXHIBITING SETDB1 INHIBITORY ACTIVITY, AND USE THEREOF | 주식회사 넷타겟 | 2024-10-24 | — | — | WO | disclosed |
| WO-2024196850-A1 | DEVELOPMENT OF HIGHLY FLUOROGENIC STYRENE PROBES FOR VISUALIZING RNA IN LIVE CELLS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-09-26 | — | — | WO | disclosed |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-12 | — | — | US | disclosed |
| CN-116940562-A | Acetamido-phenylbenzamide derivatives and methods of use thereof | 希华医药有限公司 | 2023-10-24 | — | — | CN | disclosed |
| WO-2023161782-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | SATYARX PHARMA INNOVATIONS PVT LTD (IN) | 2023-08-31 | — | — | WO | disclosed |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
| EP-4225745-A1 | ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME | Athenex, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-1077572-C | Substituted bisindolylmaleimides for inhibition of cell proliferation | HOFFMANN LA ROCHE (CH) | 2002-01-09 | — | — | CN | disclosed |
| US-6030994-A | ANTIPROLIFERATIVE, TUMOR AND CARCINOGENIC AGENTS; PARTICULARLY FOR TREATMENT OF SOLID TUMORS AND THOSE OF THE BREAST AND COLON | HOFFMANN-LA ROCHE INC. (US) | 2000-02-29 | — | — | US | disclosed |
| CN-1226249-A | Substituted bisindolylmaleimides for inhibition of cell proliferation | HOFFMANN LA ROCHE (CH) | 1999-08-18 | — | — | CN | disclosed |
| EP-0915871-A1 | SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION | F. HOFFMANN-LA ROCHE AG (CH) | 1999-05-19 | — | — | EP | disclosed |
| EP-0915872-A1 | SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION | F. HOFFMANN-LA ROCHE AG (CH) | 1999-05-19 | — | — | EP | disclosed |
| US-5891901-A | ANTICARCINOGENIC AGENTS OR ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1999-04-06 | — | — | US | disclosed |
| US-5856517-A | ANTIPROLIFERATIVE AGENTS USEFUL IN THE TREATMENT OF CANCER. | HOFFMANN-LA ROCHE INC. (US) | 1999-01-05 | — | — | US | disclosed |
| WO-1998004553-A1 | SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION | F.HOFFMANN-LA ROCHE AG (CH) | 1998-02-05 | — | — | WO | disclosed |
| WO-1998004552-A1 | SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION | F. HOFFMANN-LA ROCHE AG (CH) | 1998-02-05 | — | — | WO | disclosed |
| US-4948796-A | TREATING CEREBO-VASCULARE DISEASES | TOYAMA CHEMICAL CO., LTD. (JP) | 1990-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | CYP2A6 131/4885GPR183 382/4885PRKCI 4424/4885 |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC6, HDAC1, HDAC3 | CYP2A6 2096/4885GPR183 3946/4885PRKCI 2011/4885 |
| US-20250145601-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | RAD51, ERCC4, ERCC2 | CYP2A6 3806/4885GPR183 3271/4885PRKCI 2647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.